Patients in the EU with giant cell arteritis (GCA), an inflammation of the arteries, could soon have the first oral targeted treatment for the disease after AbbVie's Rinvoq was recommended for ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes inflammation of the large arteries.

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel ...

Rinvoq is a Key Top-Line Driver for AbbVie Rinvoq is a key top-line driver for AbbVie. The drug generated sales of almost $6 billion in 2024, which was up 50.4% year over year, owing to continuous ...